reviewTop 1% cited
Breast Cancer Treatment
JAMA · 2019 · Vol. 321(3) · pp. 288–288
Adrienne G. Waks✉(Dana-Farber Cancer Institute)Eric P. Winer(Dana-Farber Cancer Institute)
Abstract
Breast cancer consists of 3 major tumor subtypes categorized according to estrogen or progesterone receptor expression and ERBB2 gene amplification. The 3 subtypes have distinct risk profiles and treatment strategies. Optimal therapy for each patient depends on tumor subtype, anatomic cancer stage, and patient preferences.
Breast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesHER2/EGFR in Cancer ResearchMedicineBreast cancerLumpectomyOncologyCancerTriple-negative breast cancerInternal medicineEstrogen receptorSystemic therapyCA15-3
MeSH terms
Antineoplastic AgentsBreast NeoplasmsCombined Modality TherapyFemaleGene AmplificationHumansNeoplasm Recurrence, LocalReceptors, EstrogenReceptors, ProgesteroneSurvival RateGenes, erbB-2Aromatase Inhibitors
Citations
4,716
FWCI
155.09
field-weighted impact
References
97
Percentile
100%
vs. same field & year
Citations per year
Cited by
Breast Cancer Statistics, 2022
CA A Cancer Journal for Clinicians · 2022 · 2,299 citations
Breast cancer statistics, 2019
CA A Cancer Journal for Clinicians · 2019 · 3,181 citations
CircRNAs: role in human diseases and potential use as biomarkers
Cell Death and Disease · 2021 · 369 citations
References
Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer
New England Journal of Medicine · 2002 · 6,156 citations
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials
The Lancet Oncology · 2013 · 1,433 citations
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Journal of Clinical Oncology · 2013 · 4,028 citations
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
The Lancet Oncology · 2009 · 1,391 citations
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
The Lancet Oncology · 2010 · 1,892 citations
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
The Lancet Oncology · 2014 · 1,796 citations
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
Journal of Clinical Oncology · 2010 · 4,231 citations
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
JNCI Journal of the National Cancer Institute · 2014 · 1,461 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.